I am proud to share our most recent paper on the landscape of alterations in HR+ breast cancer prevention- and post-1L. We addressed challenges inherent to working with RWD, and validated our findings using clinical trial data. Great collaborations across Genentech/Roche.
Impressive multiomics analysis by the Sorger Lab uncovers the potential clinical relevance of the differential kinase polypharmacology between the "CDK4/6 drugs" abemaciclib, palbociclib and ribociclib @CellChemBiol https://t.co/ZT3L198wWk
My latest postdoc article on CDK46 inhibitors in breast cancer is out: https://t.co/ddG8WoNUT8
Thanks to Caitlin Mills, @rskartik and others for the great collaboration
#CDK46#breastcancer#CancerResearch#sysbio
Latest version of our paper: Multi-omics profiling establishes the polypharmacology of FDA Approved CDK4/6 inhibitors and its impact on… https://t.co/yseZJR0rJU